Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma

NCT02544308 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Plasmacytoma

Interventions

DRUG: Lenalidomide
DRUG: Dexamethasone
OTHER: No further treatment

Sponsor

University College, London

Collaborators

[object Object]
[object Object]